On Monday, Edgewise Therapeutics Inc (NASDAQ: EWTX) trading session started at the price of On Monday, that was -3.22% drop from the session before settling in for the closing price of $13.03. A 52-week range for EWTX has been $10.60 – $38.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.00% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -20.45%. With a float of $77.09 million, this company’s outstanding shares have now reached $95.21 million.
In an organization with 110 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Edgewise Therapeutics Inc stocks. The insider ownership of Edgewise Therapeutics Inc is 26.72%, while institutional ownership is 74.46%. The most recent insider transaction that took place on May 02 ’25, was worth 25,520. In this transaction Chief Scientific Officer of this company sold 1,551 shares at a rate of $16.45, taking the stock ownership to the 18,521 shares. Before that another transaction happened on May 02 ’25, when Company’s General Counsel sold 1,930 for $16.45, making the entire transaction worth $31,757. This insider now owns 6,531 shares in total.
Edgewise Therapeutics Inc (EWTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.76% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
You can see what Edgewise Therapeutics Inc (EWTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 20.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -2.01 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.59 million. That was inferior than the volume of 1.38 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.41%.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 10.34%, which indicates a significant decrease from 14.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.18% in the past 14 days, which was lower than the 79.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.65, while its 200-day Moving Average is $24.05. However, in the short run, Edgewise Therapeutics Inc’s stock first resistance to watch stands at $12.91. Second resistance stands at $13.22. The third major resistance level sits at $13.42. If the price goes on to break the first support level at $12.41, it is likely to go to the next support level at $12.21. Assuming the price breaks the second support level, the third support level stands at $11.90.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
There are 105,200K outstanding shares of the company, which has a market capitalization of 1.33 billion. As of now, sales total 0 K while income totals -133,810 K. Its latest quarter income was 0 K while its last quarter net income were -40,800 K.
